Deal Details

EyePoint Completes $161.0 Million Follow-On Offering

Healthcare

EyePoint follow-on offering

Summary

EyePoint Pharmaceuticals, Inc. (“EyePoint”) (NASDAQ: EYPT) recently completed an upsized underwritten public offering (the “Offering”) of 14,636,363 of its common stock, including the full exercise of the underwriters’ option to purchase additional common stock, at a price of $11.00 per share, generating gross proceeds of $161.0 million. EyePoint intends to use the net proceeds from the Offering to advance clinical development of DURAVYU™ for wet age related macular degeneration (“wet AMD”) and diabetic macular edema (“DME”), as well as support its earlier stage pipeline development initiatives and for general corporate purposes.

Baird served as a co-manager on this Offering.

About

EyePoint is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to help improve the lives of patients with serious retinal diseases. EyePoint’s pipeline leverages its proprietary bioerodible Durasert E™ technology for sustained intraocular drug delivery. EyePoint’s lead product candidate, DURAVYU™ (f/k/a EYP-1901), is an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with bioerodible Durasert E™. DURAVYU is presently in Phase 3 global, pivotal clinical trials as a sustained delivery treatment for wet AMD, the leading cause of vision loss among people 50 years of age and older in the United States, and in a Phase 2 clinical trial in DME. EyePoint is headquartered in Watertown, Massachusetts.

Healthcare

EyePoint follow-on offering